A new gold-based drug slows tumor growth by 82% in animals and targets cancer cells more precisely than chemotherapy.
Scientists at Weill Cornell Medicine have uncovered a critical mechanism driving the growth of treatment-resistant prostate ...
An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, according to a new study. The results could potentially lead to new therapies ...
A new gold-based drug can slow tumour growth in animals by 82% and target cancers more selectively than standard chemotherapy ...
Just as crop-devouring insects evolve to resist pesticides, cancer cells can increase their lethality by developing ...
A technology has been developed that can analyze tumor mutations in lung cancer patients to confirm drug resistance to ...
Discover how ADCs are advancing oncology, the regulatory challenges they face, and the promise they hold for the future of ...
Researchers explore how established agricultural pest management strategies could be adapted to address cancer therapy. The pioneering method opens new possibilities for controlling drug resistance ...
The company has an extensive IP portfolio, valid through 2040, and a drug pipeline in different preclinical and clinical stages, tar ...
The FDA will review an application to consider potential approval of Nubeqa plus androgen deprivation therapy for metastatic ...